Home / Leaderboard / Iron Triangle Partners LP
Iron Triangle Partners LP
Kevin Molloy · Hedge Fund · Long/Short Equity
Iron Triangle Partners LP is a specialized investment management firm established in 2019 by Kevin Molloy, a former healthcare investment leader at Jana Partners. Based in Cos Cob, Connecticut, the firm focuses on the global healthcare sector, including biotechnology, pharmaceuticals, and medical technology. The institution seeks to provide discretionary investment advice through an opportunistic equity strategy, leveraging deep industry expertise to navigate complex regulatory and clinical landscapes. Since its inception, the firm has focused on generating absolute returns by identifying high-conviction opportunities within its niche focus area.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +44.6% |
| YTD return | +16.6% |
| Sharpe ratio | 3.72 |
| Win rate | 85% |
| AUM | $0.8B |
| Inception | Oct 1, 2025 |
| Updated | Sep 22, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $0.8B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | http://www.irontrianglepartners.com |
Current Holdings
Updated on Sep 22, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| CVS | CVS Health Corp | 8.0% | +12.9% |
| CRL | Charles River Laboratories | 7.6% | +63.5% |
| DXCM | DexCom Inc | 7.4% | +33.3% |
| LLY | Eli Lilly and Company | 6.4% | +42.0% |
| EXAS | EXACT Sciences Corporation | 6.4% | +85.9% |
| BTSG | BrightSpring Health Services, Inc. Common Stock | 6.1% | +89.5% |
| RGEN | Repligen Corporation | 5.6% | +26.5% |
| GH | Guardant Health Inc | 5.6% | +182.8% |
| MDT | Medtronic PLC | 5.5% | -4.7% |
| ABBV | AbbVie Inc | 5.4% | +12.5% |
| GKOS | Glaukos Corp | 5.2% | +92.2% |
| BKD | Brookdale Senior Living Inc | 4.2% | +33.1% |
| ADPT | Adaptive Biotechnologies Corp | 4.2% | -53.0% |
| MDGL | Madrigal Pharmaceuticals Inc | 3.8% | +15.5% |
| CAH | Cardinal Health Inc | 3.7% | +40.9% |
| FOLD | Amicus Therapeutics Inc | 3.5% | +87.9% |
| THC | Tenet Healthcare Corporation | 3.4% | +32.1% |
| JAZZ | Jazz Pharmaceuticals PLC | 3.1% | +75.7% |
| AHCO | Adapthealth Corp | 2.5% | -45.9% |
| VCYT | Veracyte Inc | 2.4% | +18.9% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Jan 23, 2026 | BUY | VCYT | 2.4% → 2.5% |
| Jan 23, 2026 | SELL | MDGL | 3.7% → 3.7% |
| Jan 23, 2026 | BUY | CRL | 7.0% → 7.6% |
| Jan 23, 2026 | SELL | FOLD | 5.2% → 3.5% |
| Jan 23, 2026 | BUY | THC | 2.6% → 3.4% |
Investment Style Analysis
Iron Triangle Partners LP is widely recognized for employing a Long/Short Equity strategy. As of Sep 22, 2026, the firm oversees approximately $0.8B in assets under management (AUM). The portfolio demonstrates a clear preference for the Diagnostics & Research and Medical Devices sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Jan 23, Iron Triangle Partners LP made a significant move by increasing exposure to VCYT. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
Iron Triangle Partners employs a fundamental, research-driven long/short equity strategy exclusively focused on the healthcare and life sciences industries. The firm’s philosophy is built on generating alpha through bottom-up stock selection while maintaining a low net exposure to the broader market to minimize beta risk. By utilizing rigorous technical analysis of clinical trials, product pipelines, and healthcare policy, the team seeks to capitalize on dislocations and growth trends within medical technology and therapeutics. The strategy prioritizes specialized, independent research to identify mispriced securities and manage risk in a sector characterized by high volatility and innovation.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with Iron Triangle Partners LP.
Similar Investment Style
Based on Long/Short Equity.
- Perceptive Advisors LLC — Joseph Edelman · 3M +3.7%
- Glenview Capital Management, LLC — Larry Robbins · 3M +10.0%
- Zweig-DiMenna Associates, Inc. — Joseph DiMenna · 3M +4.4%
- Redmile Group, LLC — Jeremy Green · 3M +3.6%
Frequently asked questions
How is the simulated portfolio for Iron Triangle Partners LP constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is Iron Triangle Partners LP's largest holding?
As of the latest filing, Iron Triangle Partners LP's top position is CVS Health Corp (CVS), representing 8.0% of the portfolio. This reflects a high-conviction bet by the institution.
What is Iron Triangle Partners LP's historical performance and risk profile?
Our simulation indicates a total return of +44.6% with a win rate of 85%. Notably, the portfolio maintains a Sharpe Ratio of 3.72, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does Iron Triangle Partners LP primarily invest in?
Iron Triangle Partners LP has a strong preference for the Diagnostics & Research sector, which makes up 22.0% of their disclosed assets. The portfolio also has exposure to Medical Devices, indicating a specific thematic focus.
Is Iron Triangle Partners LP's portfolio concentrated or diversified?
Iron Triangle Partners LP runs a moderately concentrated portfolio with 20 disclosed positions. The top 3 holdings alone account for 23.1% of the total portfolio weight, suggesting a strategy that favors broader market exposure.
How has Iron Triangle Partners LP performed in 2026?
Our AI-simulated model portfolio for Iron Triangle Partners LP tracks a Year-to-Date (YTD) return of +16.6%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Kevin Molloy manage Iron Triangle Partners LP directly?
Yes, Kevin Molloy serves as the key portfolio manager for Iron Triangle Partners LP, overseeing the investment strategy and final capital allocation decisions.